I doubt they would make the deadline even if they get FDA...

I doubt they would make the deadline even if they get FDA approval given it's expected end of July so this could be a blessing in disguise as I think it's currently too attractive (maybe they didn't think that the market would value their technology this much and worth that much to the market, hence initially offer so much performance based shares for only revenue of $20M), it should be amended to make it more attractive to shareholders.

The ones end of this month are options.

Details Performance Shares
Each of the 93,750,000 Performance Shares will convert to one (1) fully paid ordinary share upon satisfaction of the relevant Milestone. Accordingly, the Performance Shares will convert into fully paid ordinary shares in the capital of the Company within 7 days of the release of the audited accounts in respect of the period in which ResApp and any subsidiaries of ResApp (or if the Company or any Related Entity of the Company is licensed to use the Licensed IP, the Company and that Related Entity) achieving aggregated gross revenue of $20,000,000 in the five years commencing on the day the Company is readmitted to quotation on ASX, being 14 July 2015.

Unlisted Options ($0.026; 31 Dec 2016) - Escrowed to 14 July 2017 5,250,000
Unlisted Options ($0.28; 29 April 2019) - Voluntarily Escrowed to 29 April 2017 4,500,000 Unlisted Options ($0.30; 29 April 2019) - Voluntarily Escrowed to 29 April 2017 1,866,667 Total 11,616,667